Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

“This muscle loss can be offset by doing resistance training and eating plenty of protein ,” Dr Mosley says. The Fast 800 now ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

At the end of the day, GLP-1s can be a powerful tool for achieving your weight loss goals, but only if they're safe and ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

Have you ever searched for information about side effects of a medication? These days, most people put the name of their drug into a search engine along with the phrase “side effects.” Whatever comes ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

The human body naturally makes a hormone called GLP-1, or Glucagon-Like Peptide-1. It helps signal fullness and stimulate insulin secretion in the body. GLP-1 drugs do something similar – but they ...

The imminent Indian patent expiry of Novo Nordisk’s global blockbuster anti-diabetic and weight loss treatment drug – the GLP ...

Healthcare stocks haven't gotten a lot of love from investors in recent years. While the market has been strong and the S&P ...